Procainamide (hydrochloride)

Procainamide hydrochloride (Procaine amide hydrochloride) is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1), which reactivates the expression of tumor suppressor factors by demethylating tumor suppressor genes. Procainamide hydrochloride induces vacuolization in various cell types and reduces cell proliferation and migration. Procainamide hydrochloride relaxes airway smooth muscle by activating potassium channels. Procainamide hydrochloride can be used in cancer and arrhythmia research[1][2][3][4][5][6].

Product Specifications

CAS Number

[614-39-1]

Product Name Alternative

Procaine amide (hydrochloride) ; SP 100 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA Methyltransferase; Potassium Channel

Type

Reference compound

Related Pathways

Epigenetics; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Procainamide-hydrochloride.html

Purity

99.89

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

O=C(NCCN(CC)CC)C1=CC=C(N)C=C1.[H]Cl

Molecular Formula

C13H22ClN3O

Molecular Weight

271.79

Precautions

H302, H315, H319, H335

References & Citations

[1]Lee BH, et al. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem. 2005;280 (49) :40749-40756.|[2]Pritchard B, et al. Procainamide. [Updated 2021 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing; 2022 Jan-.|[3]Gardner I, et al. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo[J]. Chemical research in toxicology, 2005, 18 (9) : 1384-1394.|[4]Nakahara T, et al. Involvement of K+ channel in procainamide-induced relaxation of bovine tracheal smooth muscle[J]. European journal of pharmacology, 2000, 402 (1-2) : 143-149.|[5]Morissette G, et al. Massive cell vacuolization induced by organic amines such as procainamide[J]. Journal of Pharmacology and Experimental Therapeutics, 2004, 310 (1) : 395-406.|[6]Segura-Pacheco B, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy[J]. Clinical Cancer Research, 2003, 9 (5) : 1596-1603.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Clin Chem. 2019 Dec;65 (12) :1522-1531. |Patent. US20180263995A1.|Adv Sci (Weinh) . 2024 Dec 5:e2410360.|Environ Pollut. 2023 Sep 1:332:121931.|Free Radic Biol Med. 2024 Jun 1:S0891-5849 (24) 00506-9.